Digestive Diseases and Sciences

, Volume 51, Issue 9, pp 1650–1657 | Cite as

A Ligand for Peroxisome Proliferator-Activated Receptor γ Inhibits Human Cholangiocarcinoma Cell Growth: Potential Molecular Targeting Strategy for Cholangioma

  • T. Kobuke
  • S. TazumaEmail author
  • H. Hyogo
  • K. Chayama
Original Paper


Peroxisome proliferator-activated receptor γ (PPARγ) ligands have an antitumor effect. The aim of this study was to clarify whether PPARγ ligands could inhibit the growth of human cholangiocarcinoma cells. PPAR( expression in HuH-28 and HuCCT1 cells (intrahepatic bile duct carcinoma) was determined using the reverse transcription-polymerase chain reaction (RT-PCR). Expression of PPARγ mRNA was detected in both cell lines. Activation of PPARγ by troglitazone caused marked growth inhibition in a time- and dose-dependent manner. Troglitazone inhibited the growth of human cholangiocarcinoma cell lines by inducing apoptosis and by cell cycle regulation (G1 arrest), and this was associated with caspase 3 and caspase 9 activation. Thus, molecular targeting with troglitazone, a nuclear receptor ligand, may be a promising strategy for treating cholangiocarcinoma, although a delivery system needs to be established.


Peroxisome proliferator-activated receptor γ Apoptosis Cell cycle 


  1. 1.
    Tontonoz P, Hu E, Spiegelman BM (1994) Stimulation of adipogenesis by PPARγ2, a lipid-activated transcription factor. Cell 79:1147–1156PubMedCrossRefGoogle Scholar
  2. 2.
    Kliwer SA, Lenhard JM, Wilson TM, Patel I, Morris DC, Lehmann JM (1995) A prostaglandin J2 metabolite binds peroxisome proliferators-activated receptor γ and promotes adipocyte differentiation. Cell 83:813–819CrossRefGoogle Scholar
  3. 3.
    Forman BM, Tontonoz P, Chen J (1995) 15-Deoxy-delta 12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 813:803–812CrossRefGoogle Scholar
  4. 4.
    Mansen A, Guardiola-Diaz H, Rafter J, et al. (1996) Expression of the peroxisome proliferators-activated receptor (PPAR) in the mouse colonic mucosa. Biochem Biophys Res Commun 222:844–851PubMedCrossRefGoogle Scholar
  5. 5.
    Fajas L, Auboef D, Raspe E, et al. (1997) The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem 272:18779–18789PubMedCrossRefGoogle Scholar
  6. 6.
    Dubuquoy L, Dharancy S, Nutten S, et al. (2002) Role of peroxisome proliferators-activated receptor γ and retinoid X receptor heterodimer in hepatogastroenterological disease. Lancet 360:1410–1418PubMedCrossRefGoogle Scholar
  7. 7.
    Kubota T, Koshizuka K, Williamson EA, et al. (1998) Ligand for peroxisome proliferators-activated receptor γ (troglitazone) has potent antitumor effect against human prostatic cancer both in vitro and in vivo. Cancer Res 58:3344–3352PubMedGoogle Scholar
  8. 8.
    Yoshizawa K, Cioca DP, Kawa S, Tanaka E, Kiyosawa K (2002) Peroxisome proliferators-activated receptor γ induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 95:2243–2251PubMedCrossRefGoogle Scholar
  9. 9.
    Sarraf P, Mueller E, Jones D, et al. (1998) Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 4:1046–1052PubMedCrossRefGoogle Scholar
  10. 10.
    Toyota M, Miyazaki Y, Kitamura S, et al. (2002) Peroxisome proliferator-activated receptor gamma reduces the growth rate of pancreatic cancer cells through the reduction of cyclin D1. Life Sci 70:1565–1575PubMedCrossRefGoogle Scholar
  11. 11.
    Eibl G, Wente MN, Reber HA, et al. (2001) Peroxisome proliferators-activated receptor γ induces pancreatic cancer cell apoptosis. Biochem Biophys Res Commun 287:522–529PubMedCrossRefGoogle Scholar
  12. 12.
    Debrock G, Vanhentenrijk V, Sciot R, Debiec–Rychter M, Oyen R, Van Oosterom A (2003) A phase II trial with rosiglitazone in liposarcoma patients. Br J Cancer 89:1409–1412PubMedCrossRefGoogle Scholar
  13. 13.
    Kitamura S, Miyazaki Y, Shimomura Y, et al. (1999) Peroxisome proliferators-activated receptor γ induces growth arrest and differentiation of human colon cancer cells. Jpn J Cancer Res 90:75–80PubMedGoogle Scholar
  14. 14.
    Rumi MA, Ishihara S, Kadowaki Y, et al. (2004) Peroxisome proliferators-activated receptor gamma–dependent and –independent growth inhibition of gastrointestinal tumor cells. Genes Cells 11:1113–1123CrossRefGoogle Scholar
  15. 15.
    Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81:323–330PubMedCrossRefGoogle Scholar
  16. 16.
    Musgrove EA, Lee CS, Buckley MF, Suthurland RL (1994) Cyclin D1 induction in breast cancer cells shortens G1 and is sufficient for cells arrested in G1 to complete the cell cycle. Proc Natl Acad Sci USA 91:8022–8026PubMedCrossRefGoogle Scholar
  17. 17.
    Morrison RF, Farmer SR (1999) Role of PPARg in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18 (INC4c) and p21 (Waf1/Cip1), during adipogenesis. J Biol Chem 274:17088–17097PubMedCrossRefGoogle Scholar
  18. 18.
    Koga H, Sakisaka S, Harada M, et al. (2003) Involvement of p21WAF/Cip1, p27Kip1, and p18INC4c in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 38:1087–1096CrossRefGoogle Scholar
  19. 19.
    Han C, Demetris AJ, Michalopoulus GK, et al. (2003) PPARγ ligands inhibit cholangiocarcinoma cell growth through p-53 dependent GADD45 and p21WAF/Cip1 pathway. Hepatology 38:167–177PubMedCrossRefGoogle Scholar
  20. 20.
    Yoshizawa K, Cioca DP, Kawa S, et al. (2002) Peroxisome proliferator-activated receptor γ ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines. Cancer 95:2243–2251PubMedCrossRefGoogle Scholar
  21. 21.
    Elsmer E, Muller C, Koshizuka K, et al. (1998) Ligands for peroxisome proliferator-activated receptor γ and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95:8806–8811CrossRefGoogle Scholar
  22. 22.
    Takahashi N, Okumura T, Motomura W, et al. (1999) Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 16:135–139CrossRefGoogle Scholar
  23. 23.
    Takahashi T, Fujiwara Y, Higuchi K, et al. (2001) PPAR-gamma ligands inhibit growth of human esophageal adenocarcinoma cells through induction of apoptosis, cell cycle arrest and reduction of ornithine decarboxylase activity. Int J Oncol 19:465–471Google Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  1. 1.Department of General Medicine and Clinical Pharmacotherapy, Graduate School of Biomedical SciencesHiroshima UniversityHiroshimaJapan

Personalised recommendations